Assessment of plasma endostatin levels in patients with acute myeloblastic and lymphoblastic leukemia Akut myeloblastik ve lenfoblastik lösemili hastalarda plazma endostatin düzeylerinin deǧerlendirilmesi
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi, cilt.21, sa.4, ss.210-216, 2011 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 21 Sayı: 4
- Basım Tarihi: 2011
- Doi Numarası: 10.4999/uhod.10015
- Dergi Adı: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.210-216
- Anahtar Kelimeler: Acute myeloblastic leukemia, Acute lymphoblastic leukemia, Angiogenesis, Endostatin
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
In this study, we evaluated the plasma levels of endostatin (PE) and its prognostic importance in patients with acute myeloblastic (AML) and lypmhoblastic leukemia (ALL). We therefore analyzed plasma levels of endostatin before the chemotherapy and during the complete remission period in adult ALL and AML patients. The PE levels of the control group were significantly lower than both cases with ALL and AML. The patients with AML during remission had significantly higher PE levels than the levels at initial diagnosis. No statistically significant difference was detected in patients with ALL. In addition, the survival rates of the cases with ALL whose PE levels are higher than 2.5 ng/ml, are significantly lower. Our results suggest that the elevated plasma levels of endostatin during the remission in patients with AML imply the intensity of angiogenesis inhibition during the remission. Furthermore our findings in ALL patients suggest that endostatin levels may predict the overall survival of these patients.